Related Experiment Video
Updated: Jul 23, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
mRNA Delivery Platform Based on Bacterial Outer Membrane Vesicles for Tumor Vaccine
Xiaoyu Gao1,2, Yao Li1,3, Guangjun Nie1,2
1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, 11 Beiyitiao, Zhongguancun, Beijing, 100190, China.
Bacteria-derived outer membrane vesicles (OMVs) engineered with L7Ae protein offer a novel platform for rapid delivery of customized tumor mRNA vaccines. This Plug-and-Display strategy bypasses limitations of current methods for personalized cancer immunotherapy.
Area of Science:
- Biotechnology
- Vaccine Development
- Nanomedicine
Background:
- Current methods for developing customized tumor mRNA vaccines face limitations in rapid display and delivery.
- Personalized cancer vaccines require efficient and adaptable delivery systems.
Purpose of the Study:
- To develop a novel mRNA delivery platform using bacteria-derived outer membrane vesicles (OMVs) for rapid, customized tumor mRNA vaccination.
- To engineer OMVs for effective mRNA antigen adsorption and cellular delivery.
Main Methods:
- Surface engineering of OMVs with an RNA-binding protein, L7Ae.
- Utilizing L7Ae-boxC/D binding for rapid adsorption of mRNA antigens.
- Demonstrating OMV-L7Ae delivery into HEK-293T cells and dendritic cells.
Main Results:
- OMVs engineered with L7Ae successfully adsorbed mRNA antigens via L7Ae-boxC/D interaction.
- The OMV-L7Ae platform demonstrated efficient delivery of mRNA into target cells.
- A Plug-and-Display strategy enabled rapid preparation of personalized mRNA tumor vaccines.
Conclusions:
- Bacteria-derived OMVs engineered with L7Ae provide a distinct and effective mRNA delivery platform for personalized tumor vaccination.
- This platform offers a rapid and adaptable alternative to lipid nanoparticles (LNPs) for cancer immunotherapy development.
More Related Videos
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy